Merck (UKEX:MRK) Cyclically Adjusted Revenue per Share: ₴931.43 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:MRK Merck & Co Inc UKEX:MRK
72 GF Score
Price ₴4,844.00
GF Value ₴4,495.22
! 9 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted Revenue per Share?

Merck UKEX:MRK 72 Cyclically Adjusted Revenue per Share is ₴931.43 as of Mar. 2026. GuruFocus rates UKEX:MRK with a GF Score™ of 72/100 and a GF Value™ of ₴4,495.22. The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck's adjusted revenue per share for the three months ended in Mar. 2026 was ₴294.378. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₴931.43 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck's average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck was 17.80% per year. The lowest was -2.50% per year. And the median was 3.40% per year.

As of today (2026-08-06), Merck's current stock price is ₴4844.00. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₴931.43. Merck's Cyclically Adjusted PS Ratio of today is 5.20.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.67.


Merck  (UKEX:MRK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4844.00/931.43
=5.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck Cyclically Adjusted Revenue per Share Related Terms


Merck Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted Revenue per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 651.42 700.72 1,033.76 1,035.44

Merck Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,348.07 1,292.23 1,035.44 931.43 0.00

UKEX:MRK vs AMGN, ABBV, GILD: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.


UKEX:MRK
72GF Score
Merck & Co Inc UKEX:MRK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=294.378/330.2130*330.2130
=294.378

Current CPI (Mar. 2026) = 330.2130.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 157.711 241.018 216.076
201609 168.980 241.428 231.122
201612 162.871 241.432 222.763
201703 152.400 243.801 206.416
201706 161.228 244.955 217.344
201709 169.178 246.819 226.339
201712 170.760 246.524 228.729
201803 165.491 249.554 218.980
201806 173.444 251.989 227.286
201809 180.099 252.439 235.586
201812 186.568 251.233 245.219
201903 185.666 254.202 241.183
201906 203.041 256.143 261.755
201909 215.370 256.759 276.983
201912 72.446 256.974 93.094
202003 211.519 258.115 270.602
202006 164.794 257.797 211.085
202009 192.410 260.280 244.107
202012 192.517 260.474 244.061
202103 186.873 264.877 232.968
202106 200.580 271.696 243.780
202109 231.765 274.310 278.998
202112 238.326 278.802 282.273
202203 280.055 287.504 321.657
202206 256.715 296.311 286.087
202209 262.946 296.808 292.540
202212 242.528 296.797 269.834
202303 253.751 301.836 277.607
202306 264.594 305.109 286.364
202309 280.136 307.789 300.545
202312 257.264 306.746 276.945
202403 277.072 312.332 292.934
202406 282.991 314.175 297.437
202409 292.909 315.301 306.762
202412 275.394 315.605 288.141
202503 274.152 319.799 283.080
202506 281.041 322.561 287.708
202509 309.023 324.800 314.173
202512 294.770 324.054 300.372
202603 294.378 330.213 294.378

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₴931.43 mean?
Merck (UKEX:MRK) has a Cyclically Adjusted Revenue per Share of ₴931.43 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted Revenue per Share too high?
Merck's current Cyclically Adjusted Revenue per Share is ₴931.43. Overall, Merck has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted Revenue per Share compare to AMGN and ABBV?
Merck's Cyclically Adjusted Revenue per Share of ₴931.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted Revenue per Share is ₴931.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Merck (UKEX:MRK) has a current Cyclically Adjusted Revenue per Share of ₴931.43. The stock's GF Value™ is ₴4,495.22, compared to a current price of ₴4,844.00 — trading 7.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₴931.43. Merck's overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck (UKEX:MRK), the current Cyclically Adjusted Revenue per Share is ₴931.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (UKEX:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of ₴4,844.00 is trading 7.8% above its estimated GF Value™ of ₴4,495.22.

Key valuation signals for UKEX:MRK:

  • Cyclically Adjusted Revenue per Share: ₴931.43
  • GF Value™: ₴4,495.22 vs. price of ₴4,844.00 (7.8% above fair value)
  • GF Score™: 72/100 with 9 warning signs

No single metric tells the full story. See the UKEX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score

Get the complete analysis for UKEX:MRK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴4,844.00
Price
₴4,495.22
GF Value